Compare Recursion Pharmaceuticals Inc (RXRX) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Schwab US Large Cap Growth ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Schwab US Large Cap Growth ETF trades at $36.59 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 30.4× Recursion Pharmaceuticals Inc's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| RXRX | SCHG | |
|---|---|---|
Market Cap | $2.14B | $65.01B |
Volume | 30,789,535 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $36.93 |
52-Week Low | $2.84 | $28.10 |
Typical Hold Time | 22 Days | 50 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
SCHG trades at $36.87, down 0.16% with a bullish technical outlook from moving averages but bearish oscillators. The ETF maintains strong growth exposure with low expense ratios, though recent news highlights concentration risks in top holdings. Dividend activity remains minimal with a $0.04 distribution scheduled for September 2026.
Growth ETF positioning favors long-term investors despite near-term overbought signals. Key risks include heavy concentration in megacap tech stocks and potential valuation compression. Analyst sentiment remains positive for strategic allocations to large-cap growth exposure with disciplined entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
